BC
ADMA icon

Broadfin Capital’s ADMA Biologics ADMA Stock Holding History

Broadfin Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-505,900
Closed -$2.25M – 42
2019
Q3 		$2.25M Sell
505,900
-241,600
-32% -$1.01M 0.42% 38
2019
Q2 		$2.89M Sell
747,500
-731,743
-49% -$3.23M 0.63% 35
2019
Q1 		$5.61M Sell
1,479,243
-2,746,834
-65% -$9.71M 1.16% 31
2018
Q4 		$10.1M Sell
4,226,077
-237,752
-5% -$1.18M 1.33% 23
2018
Q3 		$27.7M Buy
4,463,829
+1,214,000
+37% +$6.99M 4.08% 5
2018
Q2 		$14.7M Buy
3,249,829
+2,529,300
+351% +$12.6M 2.31% 16
2018
Q1 		$3.31M Sell
720,529
-381,671
-35% -$1.52M 0.52% 43
2017
Q4 		$3.54M Buy
+1,102,200
New +$3.08M 0.58% 35
2017
Q3 		– Sell
-681,346
Closed -$2.52M – 46
2017
Q2 		$2.52M Sell
681,346
-347,326
-34% -$1.39M 0.31% 44
2017
Q1 		$5.02M Sell
1,028,672
-84,621
-8% -$417K 0.61% 35
2016
Q4 		$5.7M Hold
1,113,293
– – 0.63% 40
2016
Q3 		$8.06M Hold
1,113,293
– – 0.72% 44
2016
Q2 		$6.62M Buy
1,113,293
+149,100
+15% +$1.04M 0.64% 40
2016
Q1 		$7.8M Hold
964,193
– – 0.75% 36
2015
Q4 		$7.78M Hold
964,193
– – 0.48% 55
2015
Q3 		$8.06M Hold
964,193
– – 0.45% 55
2015
Q2 		$8.93M Hold
964,193
– – 0.48% 46
2015
Q1 		$9.45M Buy
964,193
+575,000
+148% +$5.79M 0.74% 38
2014
Q4 		$4.35M Buy
+389,193
New +$4.45M 0.38% 55

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return

Broadfin Capital's ADMA Position: Q4 2019 in Review

Broadfin Capital sold out of ADMA Biologics (ADMA) in Q4 2019, closing a stake of 505,900 shares — an estimated $2.25M sold.

Broadfin Capital first reported a position in ADMA in Q4 2014 and held it in 19 quarters. The position peaked at $27.7M in Q3 2018. 74 funds tracked by Wall St. Rank hold ADMA as of Q4 2019.

  • Broadfin Capital reported no remaining ADMA Biologics position as of Q4 2019 after selling out during the quarter.
  • Broadfin Capital sold 505,900 ADMA Biologics shares in Q4 2019, an estimated $2.25M.
  • Broadfin Capital first reported a position in ADMA Biologics in Q4 2014 and held it in 19 quarters.
  • Broadfin Capital's ADMA Biologics position peaked at $27.7M in Q3 2018.
  • 74 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.